Применение лекарственных средств УДК 616-006.441 Kryachok I., Filonenko K., Skrypets T., Titorenko I., Aleksik O., Kadnikova T., Novosad O., Pastushenko Y., Stepanishina Y., Martynchyk A., Kushchevyy E., Ulianchenko K. National Cancer Institute, Kiev, Ukraine Крячок И., Филоненко К., Скрипец Т., Титоренко И., Алексик Е., Кадникова Т., Новосад О., Пастушенко Я., Степанишина Я., Мартынчик А., Кущевой Е., Ульянченко К. <...> Национальный Институт Рака, Киев, Украина Evaluation of the effi cacy of thromboprophylaxis with rivaroxaban in patients with lymphoproliferative disorders Оценка эффективности тромбопрофилактики с применением ривароксабана у пациентов с лимфопролиферативными заболеваниями __________________________________________________________________________________________________________ Резюме Венозная тромбоэмболия (ВТЭ) – частое осложнение у пациентов с онкологическими заболеваниями. <...> Ривароксабан (cелективный прямой ингибитор фактора Ха для приема внутрь) может быть отличной альтернативой и опцией для тромбопрофилактики у пациентов с онкозаболеваниями. <...> Venous thromboembolism (VTE) is a frequent complication in cancer patients. <...> Aim of our study was to compare incidence of VTE and level of complications in patients who received rivaroxaban or other anticoagulants for prophylaxis of cancer-related VTE. <...> In the Oncohematology department of National Cancer Institute we started to use rivaroxaban for prophylaxis of cancer-related VTE since 2012. <...> All patients with lymphoproliferative disorders (LPD), both newly diagnosed and relapsed, treated in the Oncohematology department of the National Cancer Institute (Kyiv, Ukraine) from 2011 till 2015 who underwent VTE prophylaxis were included into analysis. <...> Patients were distinguished between two groups: those who received rivaroxaban and other anticoagulants. <...> Both groups were compared by the cancer type, age, gender, stage of the disease, number of risk factors by Khorana index. <...> We revealed 46 patients with LPD who underwent prophylaxis of cancer-related VTE in our data base. <...> And made the comparison of the treatment effi cacy and toxicity «Евразийский онкологический журнал», 2017, том 5, № 2 231 Оценка эффективности тромбопрофилактики с применением ривароксабана у пациентов с лимфопролиферативными заболеваниями according to the prescribed anticoagulant drug only in the group of patients who received primary prophylaxis. <...> Th <...>